Nippon Life Global Investors Americas Inc. Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Nippon Life Global Investors Americas Inc. bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, Holdings Channel reports. The fund bought 14,610 shares of the medical research company’s stock, valued at approximately $7,331,000.

A number of other institutional investors and hedge funds have also modified their holdings of TMO. Flputnam Investment Management Co. acquired a new position in Thermo Fisher Scientific in the second quarter valued at approximately $33,834,000. Horizon Investment Services LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth $311,000. Global Retirement Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $4,085,000. Titiun Yejiel acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $2,628,000. Finally, 1ST Source Bank bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth $8,088,000. 89.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Morgan Stanley boosted their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their price target for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Piper Sandler boosted their price objective on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a report on Monday, July 27th. Finally, KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $619.41.

Insiders Place Their Bets

In related news, VP Lisa P. Britt sold 5,850 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $580.00, for a total value of $3,393,000.00. Following the sale, the vice president owned 14,784 shares of the company’s stock, valued at approximately $8,574,720. The trade was a 28.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 4,608 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $586.12, for a total value of $2,700,840.96. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 52,053 shares of company stock valued at $30,643,589 in the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Down 0.3%

NYSE:TMO opened at $586.62 on Tuesday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99. The company has a market cap of $216.90 billion, a P/E ratio of 31.56, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84. The business has a 50 day moving average price of $531.72 and a two-hundred day moving average price of $508.48.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same quarter in the previous year, the firm posted $4.28 earnings per share. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.